LEXICON PHARMACEUTICALS, INC. Long-Term Debt
LEXICON PHARMACEUTICALS, INC. (LXRX) had Long-Term Debt of $51.44 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:LongTermDebtNoncurrent · last filed 2026-08-06
- 2026-06-30: Long-term Debt, Excluding Current Maturities $51.44M.
- 2026-03-31: Long-term Debt, Excluding Current Maturities $49.68M.
- 2025-12-31: Long-term Debt, Excluding Current Maturities $49.41M.
- 2025-09-30: Long-term Debt, Excluding Current Maturities $56.51M.
| Period end | Long-term Debt, Excluding Current Maturities | Long-term Debt, Excluding Current Maturities as first filed |
|---|---|---|
| 2026-06-30 | $51.44M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $49.68M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $49.41M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $56.51M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $56.11M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $58.64M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $100.30M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $99.89M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $99.50M 10-Q · filed 2024-08-02 | |
| 2024-03-31 | $99.87M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $99.51M 10-K · filed 2025-03-07 | |
| 2023-09-30 | $99.27M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $98.77M 10-Q · filed 2023-08-04 | |
| 2023-03-31 | $48.84M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $48.58M 10-K · filed 2024-03-25 | |
| 2022-09-30 | $23.78M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $23.63M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $23.48M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $0.00 10-K · filed 2023-03-03 | |
| 2020-12-31 | $0.00 10-K · filed 2021-03-12 | |
| 2020-09-30 | $11.63M 10-Q · filed 2020-10-30 | |
| 2020-06-30 | $234.81M 10-Q · filed 2020-07-29 | |
| 2020-03-31 | $234.49M 10-Q · filed 2020-04-27 | |
| 2019-12-31 | $234.17M 10-K · filed 2021-03-12 | |
| 2019-09-30 | $233.84M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $243.95M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $243.91M 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $243.89M 10-K · filed 2020-03-12 | |
| 2018-09-30 | $243.83M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $232.20M 10-Q · filed 2018-07-30 | |
| 2018-03-31 | $231.88M 10-Q · filed 2018-05-03 | |
| 2017-12-31 | $231.58M 10-K · filed 2019-03-15 | |
| 2017-09-30 | $85.51M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $85.38M 10-Q · filed 2017-08-01 | |
| 2017-03-31 | $85.27M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $85.17M 10-K · filed 2018-03-01 | |
| 2016-09-30 | $85.04M 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $84.91M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $100.55M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $100.96M 10-K · filed 2017-03-06 | $103.79M 10-K · filed 2016-03-11 |
| 2015-09-30 | $87.50M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $87.50M 10-Q · filed 2015-08-07 | |
| 2015-03-31 | $87.50M 10-Q · filed 2015-05-05 | |
| 2014-12-31 | $87.50M 10-K · filed 2016-03-11 | |
| 2014-09-30 | $0.00 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $19.25M 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $19.71M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $20.17M 10-K · filed 2015-03-12 | |
| 2013-09-30 | $20.61M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $0.00 10-Q · filed 2013-08-01 | |
| 2013-03-31 | $21.46M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $21.88M 10-K · filed 2014-03-07 | |
| 2012-09-30 | $22.28M 10-Q · filed 2012-11-07 | |
| 2012-06-30 | $22.68M 10-Q · filed 2012-08-02 | |
| 2012-03-31 | $23.06M 10-Q · filed 2012-05-03 | |
| 2011-12-31 | $23.45M 10-K · filed 2013-03-11 | |
| 2011-09-30 | $23.83M 10-Q · filed 2011-11-01 | |
| 2011-06-30 | $24.19M 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $27.34M 10-K · filed 2012-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |